These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1385 related articles for article (PubMed ID: 26566863)
21. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
23. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair. Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938 [TBL] [Abstract][Full Text] [Related]
24. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Beier D; Schulz JB; Beier CP Mol Cancer; 2011 Oct; 10():128. PubMed ID: 21988793 [TBL] [Abstract][Full Text] [Related]
25. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474 [TBL] [Abstract][Full Text] [Related]
26. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235 [TBL] [Abstract][Full Text] [Related]
27. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583 [TBL] [Abstract][Full Text] [Related]
28. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956 [TBL] [Abstract][Full Text] [Related]
29. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Munoz JL; Walker ND; Scotto KW; Rameshwar P Cancer Lett; 2015 Oct; 367(1):69-75. PubMed ID: 26208431 [TBL] [Abstract][Full Text] [Related]
30. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma. Lan F; Pan Q; Yu H; Yue X J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. Beier D; Schriefer B; Brawanski K; Hau P; Weis J; Schulz JB; Beier CP J Neurooncol; 2012 Aug; 109(1):45-52. PubMed ID: 22544650 [TBL] [Abstract][Full Text] [Related]
32. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma. Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H J Neurosurg; 2021 Mar; 134(3):701-710. PubMed ID: 32168477 [TBL] [Abstract][Full Text] [Related]
33. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Fukushima T; Takeshima H; Kataoka H Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445 [TBL] [Abstract][Full Text] [Related]
34. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. Wang HH; Chang TY; Lin WC; Wei KC; Shin JW Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714 [TBL] [Abstract][Full Text] [Related]
35. Downregulating DNA methyltransferase 3B by suppressing the PI3K/Akt signaling pathway enhances the chemosensitivity of glioblastoma to temozolomide. Kan W; Gao L; Chen J; Chen L; Zhang G; Hao B; He M; Chen X; Wang C Mol Neurobiol; 2024 Sep; 61(9):7066-7074. PubMed ID: 38368287 [TBL] [Abstract][Full Text] [Related]
36. PARP inhibition suppresses the emergence of temozolomide resistance in a model system. Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246 [TBL] [Abstract][Full Text] [Related]
37. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123 [TBL] [Abstract][Full Text] [Related]